Gland Pharma informs about press release
Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; Gland Pharma has informed that it attached announcement regarding the receipt of USFDA tentative approval for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC).
The above information is a part of company’s filings submitted to BSE.
